Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with EGFR positive advanced solid tumors, such as lung cancer, colorectal cancer and ovary cancer.
Advanced EGFR-positive Solid Tumors
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors|
- Occurrence of study related adverse events [ Time Frame: Until week 24 ] [ Designated as safety issue: Yes ]
- Anti-leukemia responses to CART-EGFR cell infusions [ Time Frame: up to 24 weeks ] [ Designated as safety issue: Yes ]
- in vivo existence of CART-EGFR [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-EGFR vector (referred to as CART-EGFR cells).
II. Determine duration of in vivo survival of CART-EGFR cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-EGFR TCR zeta:CD137 and TCR (T-cell receptor) zeta cells over time.
I. For patients with detectable disease, measure anti-tumor response due to CART-EGFR cell infusions.
II. Estimate relative trafficking of CART-EGFR cells in tumor bed.
III. Determine if cellular or humoral host immunity develops against the murine anti-EGFR, and assess correlation with loss of detectable CART-EGFR (loss of engraftment).
IV. Determine the relative subsets of CART-EGFR T cells (Tcm, Tem, and Treg).
OUTLINE: Patients are assigned to 1 group according to order of enrollment.
Patients receive anti-EGFR-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells on days 0,1, and 2 in the absence of unacceptable toxicity.
After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 13 years.
Estimate relative trafficking of CART-EGFR cells in peripheral blood.
|Contact: weidong han, Dr.||firstname.lastname@example.org|
|Contact: kaichao feng, Dr.||email@example.com|
|Chinese PLA General Hospital||Recruiting|
|Beijing, Beijing, China, 100853|
|Contact: weidong han, Dr. 86-10-13651392893 firstname.lastname@example.org|
|Contact: Kaichao Feng, Dr. 86-10-13811421950 email@example.com|
|Principal Investigator: Yao Wang, Dr.|
|Study Chair:||weidong han, Dr.||Chinese PLA General Hospital|